Investor Relation

Reply Slip for the Second Extraordinary General Meeting for the Year 2024

Proxy Form for the Second Extraordinary General Meeting for the Year 2024

Notice of Extraordinary General Meeting

(1) Continuing Connected Transactions; And(2) Notice of Extraordinary General Meeting

Overseas Regulatory Announcement-Announcement on Febuxostat Tablets Having Obtained the Drug Registration Certificate

Announcement on Calcium Gluconate Injection Passing the Generics Consistency Evaluation

Announcement on Pentazocine Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs

Announcement on Drugs of Wholly-owned Subsidiary Passing the Generics Consistency Evaluation

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2024

Change of Branch Share Registrar and Transfer Office in Hong Kong